[{"id":"032935d4-55fb-42dd-9d89-56ed868d4ba8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03229278","created_at":"2021-01-18T15:56:22.342Z","updated_at":"2024-07-02T16:35:26.954Z","phase":"Phase 1","brief_title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","source_id_and_acronym":"NCT03229278","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Vyglxia (troriluzole)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 10/20/2022","primary_completion_date":" 10/20/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-12-06"}]